Talis Biomedical

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.

Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

Duluth Hlds

Groupon

Sonida Senior Living

Vroom

Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel.

7 Small-Cap Stocks to Sell in August Before They Crash and Burn

Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical Second Quarter Results and Business Update Conference Call.

Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript

REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In order to regain compliance, the Company's common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days which the Company satisfied on July 19, 2023. Accordingly, the Notice stated that Nasdaq now considers the matter closed.

Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement

REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”). The Company's common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on July 6, 2023.

Talis Biomedical Announces 1-for-15 Reverse Stock Split

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company's February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached thei.

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director

Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.

Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced a business update and reported financial results for the first quarter ended March 31, 2023.

Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023

SAN DIEGO--(BUSINESS WIRE)---- $TLIS #COVID19--Class Action Against Talis Biomedical Corporation (TLIS) Survives Motion to Dismiss.

Talis Biomedical Corporation (TLIS) Stockholders: Robbins LLP is Investigating TLIS on Behalf of Shareholders

Baxter

PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION11 April 2023, 22:00 CEST Biocartis appoints Roger Moody as new CEO Roger Moody to be a ppointed as new Chief Executive Officer and member of the Board of Directors Herman Verrelst , current Chief Executive Officer , will move into the position of Executive Chairman of the Board of Directors Addit ional extensive experience in the US diagnostic market while leveraging existing knowledge and relationships Mechelen, Belgium, 11 April 202 3 - Biocartis Group NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces changes to its executive management. Roger Moody has been appointed to the position of Chief Executive Officer effective 24 April 2023.

Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO

REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Talis Announces Fourth Quarter and Full Year 2022 Financial Results

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended September 30, 2022.

Talis Biomedical Reports Third Quarter 2022 Financial Results

Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Roger Moody - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Mike Ryskin - Bank of America Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.

Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q2 2022 Results - Earnings Call Transcript

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Talis Biomedical Provides Business Update and Reports Second Quarter Financial Results

Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Emily Faucette - SVP-Corporate Communications and IR Rob Kelley - CEO Roger Moody - CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Mark Massaro - BTIG Operator Thank you all for standing by, and welcome to Talis's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I'll now turn the call over to your host, Emily Faucette.

Talis Biomedical Corporation(TLIS) CEO Rob Kelly on Q12022 Results - Earnings Call Transcript

Talis Biomedical Announces First Quarter 2022 Financial Results

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

Shares of Talis Biomedical Corp. TLIS, +2.34% bounced 1.9% in midday trading Monday, after the diagnostic testing company requested a withdrawal of a large share offering by a selling shareholder. After the March 15 closing bell, the company had registered 37.49 million common shares for sale, including 7.63 million common shares and 29.86 million shares issuable after the conversion of convertible preferred stock, by entities affiliated with Baker Bros.

Talis Biomedical stock bounces off record low after largest shareholder pulls share-sale plans

Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q4 2021 Results - Earnings Call Transcript

News for Talis Biomedical Stock (TLIS)